

**Supplementary Table 1.** American Society for Gastrointestinal Endoscopy 2010 Risk Stratification Tool

Risk category

High: Presence of 1 “very strong” criteria OR both “strong” criteria

Low: No criteria met

Intermediate: All other patients

Very strong criteria

CBD stone visualized on transabdominal US

Clinical evidence of cholangitis

Total bilirubin >4 mg/dL

Strong criteria

Dilated CBD on US (>6 mm)

Total bilirubin level 1.8–4 mg/dL

Moderate criteria

Abnormal LFTs

Age >55 yr

CBD, common bile duct; LFT, liver function test result.

**Supplementary Table 2.** American Society for Gastrointestinal Endoscopy 2019 Risk Stratification Tool

Risk category

High: Presence of any high risk criteria

Low: No criteria met

Intermediate: All other patients

High risk criteria

CBD stone visualized on transabdominal US OR CT scan

Total bilirubin >4 mg/dL AND dilated CBD on imaging (>6 mm)

Clinical evidence of cholangitis

Moderate risk criteria

Abnormal LFTs

Bilirubin >1.8 mg/dL

Dilated CBD on imaging

Age >55 yr

CBD, common bile duct; CT, computed tomography; LFT, liver function test result.